Targeting cannabinoid CB2 receptors in the Central Nervous System. Medicinal chemistry approaches with focus on neurodegenerative disorders

Frontiers in Neuroscience

Paula Morales¹  Nadine Jagerovic¹  Carmen Rodríguez-Cueto²  Javier Fernández-Ruiz²  Gema Navarro³  Rafael Franco³ 

[1] Consejo Superior de Investigaciones Cientificas;Universidad Complutense de Madrid;University of Barcelona;

关键词: Amyotrophic Lateral Sclerosis;    Cerebellar Ataxia;    Microglia;    Neuroprotection;    heteromers;    Parkinson’s disease;   

DOI  :  10.3389/fnins.2016.00406

来源: DOAJ

【 摘 要 】

Endocannabinoids activate two types of specific receptors, namely cannabinoid CB1 and CB2. Contrary to the psychotropic actions of agonists of CB1 receptors, and serious side effects of the selective antagonists of this receptor, drugs acting on CB2 receptors appear as promising drugs to combat CNS diseases. Differential localization of CB2 receptors in neural cell types and upregulation in neuroinflammation are keys to understand the therapeutic potential in inter alia diseases that imply progressive neurodegeneration. Medicinal chemistry approaches are now engaged to develop imaging tools to map receptors in the living human brain, to develop more efficacious agonists, and to investigate the possibility to develop allosteric modulators.

【 授权许可】

Unknown